Specific Antihypertensive Agents in ACS 1389 5.3.1. Nitroglycerin 1389 -Blockers 1390 Calcium Channel Blockers 1390 5.3.4. ACE Inhibitors 1390 Angiotensin Receptor Blockers 1391 5.3.6. Aldosterone Antagonists 1391 5.3.7. Diuretics 1391 Safety of Anticoagulation in Patients With Uncontrolled Hypertension 1391 5.5. Conclusions 1391 5.6. Recommendations 1392 Management of Hypertension in HF of Ischemic Origin 1392 Hypertension and HF 1392 6.2. Demographics 1392 Hypertension and HF Pathophysiology 1393 CAD and Acute HF 1393 6.5. Therapeutic Strategies 1393 6.6. Nonpharmacological Therapies 1393 6.7. Pharmacological Therapies 1393 6.7.1. Diuretics 1393 6.7.2. ACE Inhibitors 1394 Angiotensin Receptor Blockers 1394 -Blockers 1394 Nitrates and Hydralazine 1395 6.7.6. Aldosterone Receptor Antagonists 1395 6.8. Renal Denervation 1395 6.9. Goal BP 1395 6.10. Drugs to Avoid 1395 6.11. Recommendations 1396 CAD prevention and management. It attempts, on the basis of the best available evidence, to develop recommendations that will be appropriate for both BP reduction and the man- agement of CAD in its various manifestations. When data are meager or lacking, the writing group has proposed consensus recommendations and has highlighted opportunities for well- designed prospective clinical trials to fill knowledge gaps. All of the discussion and recommendations refer to adults. The writing committee has not addressed hypertension or IHD in the pediatric age group. In addition, there is no discussion of the different modes of assessing BP, including 24-hour ambulatory BP monitoring. These were the subject of an AHA scientific statement in 2005.2 Recommendations, with levels of evidence, have been developed according to the AHA format shown in Table 1. The general design of the scientific statement is based on the concept that each of the clinical sections refers to a particular subset of patients, so each section should pro- vide a stand-alone description of the recommendations and their justification independently of the other sections. 